- Home
- IBRX vs DSGX Comparison
IBRX vs DSGX Comparison
Compare IBRX & DSGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBRX | DSGX |
|---|---|---|
| Founded | 2014 | 1981 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.2B |
| IPO Year | 2015 | 1999 |
Fundamental Metrics
Financial Performance| Metric | IBRX | DSGX |
|---|---|---|
| Price | $9.17 | $71.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | $12.57 | ★ $105.22 |
| AVG Volume (30 Days) | ★ 11.7M | 576.4K |
| Earning Date | 05-08-2026 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $113,288,000.00 | N/A |
| Revenue This Year | $88.59 | $12.05 |
| Revenue Next Year | $131.15 | N/A |
| P/E Ratio | ★ N/A | $37.05 |
| Revenue Growth | ★ 668.31 | N/A |
| 52 Week Low | $1.95 | $62.56 |
| 52 Week High | $12.43 | $108.51 |
Technical Indicators
Market Signals| Indicator | IBRX | DSGX |
|---|---|---|
| Relative Strength Index (RSI) | 70.92 | 51.29 |
| Support Level | $6.69 | $69.44 |
| Resistance Level | $9.54 | $74.57 |
| Average True Range (ATR) | 0.55 | 2.64 |
| MACD | 0.23 | -0.07 |
| Stochastic Oscillator | 90.94 | 58.44 |
Price Performance
Historical ComparisonAbout IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
About DSGX Descartes Systems Group Inc. (The)
Descartes Systems Group provides a software solution that allows users in the shipping industry to communicate with one another. Its core product is the Global Logistics Network, which is best understood as transaction-driven. Descartes charges clients to send/receive messages, data, and documents on the GLN. Customers typically contract for a monthly minimum over a multiyear period. The GLN platform allows Descartes to upsell additional software modules as well, typically provided via a software-as-a-service model.